ライフサイエンスコーパス: Cancer Center

1 database at University of Texas MD Anderson Cancer Center.

2 eated at The University of Texas MD Anderson Cancer Center.

3 al Cancer Institute-designated comprehensive cancer center.

4 an academic dermatologic surgery section and cancer center.

5 logy Service of the Memorial Sloan Kettering Cancer Center.

6 al Cancer Institute-designated comprehensive cancer center.

7 NGS (236-404 genes) in an academic tertiary cancer center.

8 2014 at the University of Texas MD Anderson Cancer Center.

9 titutes of Health and the Mayo Comprehensive Cancer Center.

10 ith untreated brain metastases from the Yale Cancer Center.

11 cember 31, 2013, in a tertiary comprehensive cancer center.

12 erapy at The University of Texas MD Anderson Cancer Center.

13 al Cancer Institute-designated comprehensive cancer center.

14 who received PST at a large US comprehensive cancer center.

15 al Cancer Institute-designated comprehensive cancer center.

16 sorectal excision (TME) at an NCI designated cancer center.

17 15, 2015, at the Dana-Farber/Brigham Women's Cancer Center.

18 terrogation data following RT at an academic cancer center.

19 and December 31, 2012, at a single tertiary cancer center.

20 ment of Breast Medical Oncology, MD Anderson Cancer Center.

21 iary medical center with a designated breast cancer center.

22 iety, National Cancer Institute, MD Anderson Cancer Center.

23 r to follow patients in collaboration with a cancer center.

24 re Tech, and University of Texas MD Anderson Cancer Center.

25 T and the hepatobilary cancer clinics at the cancer center.

26 chemotherapy varied significantly by type of cancer center.

27 est Oncology Group [SWOG]) or at MD Anderson Cancer Center.

28 s, healthcare personnel, and visitors in the cancer center.

29 leforSurvival Fund, Memorial Sloan-Kettering Cancer Center.

30 diatric patients at Memorial Sloan-Kettering Cancer Center.

31 d Cancer Center and Memorial Sloan Kettering Cancer Center.

32 stitutes of Health National Cancer Institute Cancer Center.

33 Cancer Society, and Sylvester Comprehensive Cancer Center.

34 misleading marketing by a single for-profit cancer center.

35 stage I-II HL who were managed at a tertiary cancer center.

36 bsite at the University of Texas MD Anderson Cancer Center.

37 rtment of Oncogenetics from the A.C. Camargo Cancer Center.

38 National Comprehensive Cancer Network (NCCN) Cancer Centers.

39 Mate 067) conducted at academic and clinical cancer centers.

40 and implications for critical care units in cancer centers.

41 ical guidelines, and best practices in major cancer centers.

42 tals, but most do not contain NCI-designated cancer centers.

43 9 National Cancer Institute (NCI)-Designated Cancer Centers.

44 at six National Cancer Institute-designated cancer centers.

45 ternational cooperative study involved 6 eye cancer centers.

46 y/American College of Surgeons Commission on Cancer centers.

47 results may not generalize outside of major cancer centers.

48 national lymphoma clinical trials groups and cancer centers.

49 c medical center with gynecologic and breast cancer centers.

50 The study included 7 international eye cancer centers.

51 rch 2, 2011, and May 21, 2013, at 8 academic cancer centers.

52 gists affiliated with NCI-Designated or NCCN Cancer Centers.

53 when considering only affiliation with NCCN Cancer Centers.

54 4 until May 2016 at Memorial Sloan Kettering Cancer Center, 10336 patients consented to tumor DNA seq

55 nal cohort study at Memorial Sloan Kettering Cancer Center, 265 men with progressive mCRPC undergoing

56 al Cancer Institute-designated Comprehensive Cancer Center, 3 in a community-based network) were qual

57 al conducted at the Memorial Sloan Kettering Cancer Center, 60 patients 18 years and older with advan

58 a National Cancer Institute (NCI)-designated cancer center (8.6% [95% CI, 8.1%-9.2%] among NCI cancer

59 ecember 2011 at the Mass General/North Shore Cancer Center, a community-based cancer center in northe

60 3, was conducted at Memorial Sloan-Kettering Cancer Center, a tertiary referral center.

61 e recruited from a National Cancer Institute cancer center, a Veterans Administration Medical Center,

62 vanced cancer at a National Cancer Institute cancer center, a Veterans Affairs Medical Center, and co

63 Even at specialty cancer centers, a sizeable minority of patients with rec

64 In a comprehensive cancer center, about one fourth of the patients required

65 Cancer center accreditation and public reporting are 2 a

66 ss screening and referral as a condition for cancer center accreditation beginning in 2015.

67 , which includes 2 academic and 10 community cancer centers across Alabama, Georgia, Florida, Mississ

68 care for patients treated at eight specialty cancer centers across the United States and was used to

69 though critics have expressed concerns about cancer center advertising, analyses of the content of th

70 6.1 years and 9.0 years for the MD Anderson Cancer Center and ACOSOG cohorts, respectively.

71 After controlling for NCCN Cancer Center and clinical TNM stage in a multivariable

72 al Cancer Institute-designated comprehensive cancer center and consented to have information stored i

73 harts of 40 such patients at a tertiary care cancer center and found that amphotericin B lipid comple

74 MD Anderson Cancer Center and Medtronic.

75 husetts General Hospital/Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center

76 University of Texas MD Anderson Cancer Center and National Cancer Institute Specialized

77 ic surgery units at Memorial Sloan Kettering Cancer Center and Oregon Health & Science University wer

78 spective database at the Dana-Farber/Harvard Cancer Center and selected a validation cohort from depa

79 the UCSF Helen Friller Family Comprehensive Cancer Center and the Mt Zion Health Fund of the Univers

80 12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphom

81 et computers in clinic waiting rooms at 9 US cancer centers and community oncology practices at 2 vis

82 Tumor samples were collected from numerous cancer centers and were examined for racial differences

83 ttee of all randomised trials at MD Anderson Cancer Center, and before a planned interim analysis of

84 Institute, the University of Michigan Rogel Cancer Center, and Incyte Corporation.

85 r Cancer Institute, Indiana University Simon Cancer Center, and Indiana Clinical and Translational Sc

86 ocytosis at the University of Michigan Rogel Cancer Center (Ann Arbor, MI, USA).

87 targeted agents at Memorial Sloan Kettering Cancer Center are offered tumor-normal sequencing with M

88 r 1, 2013, through December 31, 2015, at the cancer center at All India Institute of Medical Sciences

89 he Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (Baltimore, MD, USA).

90 lysis at The University of Texas MD Anderson Cancer Center based on prospectively collected data.

91 ted to the acute palliative care unit of our cancer center because of debilitating fatigue.

92 he patients were treated at The New York Eye Cancer Center, Beth Israel Comprehensive Cancer Center,

93 isolated from a patient in our comprehensive cancer center between 1 January 2006 and 15 October 2013

94 s were performed at Memorial Sloan Kettering Cancer Center between 1992 and 2012, from which 2368 pat

95 This trial was done at MD Anderson Cancer Center between 1999 and 2001 (protocol number 98-

96 ancreatic NETs treated at the H. Lee Moffitt Cancer Center between 1999 and 2010 were assigned a stag

97 eocecal NETs who were treated at the Moffitt Cancer Center between 2000 and 2010 were assigned stages

98 ed in a breast cancer registry at a tertiary cancer center between 2000 and 2016 were evaluated for g

99 III breast cancer who were seen at a single cancer center between 2010 and 2012, and who agreed to p

100 nts treated with (177)Lu-DOTATATE at Moffitt Cancer Center between April 2018 and October 2019 were e

101 matology Service at Memorial Sloan Kettering Cancer Center between January 1, 2014, and December 31,

102 PDAC and hospitalized at the China National Cancer Center between January 1999 and January 2016 were

103 ion for lymphoma at Memorial Sloan-Kettering Cancer Center between January 2005 and December 2009 and

104 py at 6 National Cancer Institute-designated cancer centers between January 1, 2004, and December 31,

105 performed in 4 high-volume Dutch esophageal cancer centers between November 2009 and April 2017.

106 carcinoma treated at the Dana-Farber/Harvard Cancer Center (Boston, MA, USA).

107 antation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CA

108 dian Institutes of Health Research, Abramson Cancer Center, Centre for Addiction and Mental Health Fo

109 ent cohorts of 154 (Memorial Sloan Kettering Cancer Center cohort [MSKCC] cohort) and 117 (Cambridge

110 ples from publicly available and MD Anderson Cancer Center cohorts.

111 Neither admission to ICUs in cancer centers compared with general hospitals nor annua

112 The number of patients managed in major cancer centers creates a challenge to the implementation

113 bel, phase 2 study of patients from the Yale Cancer Center (CT, USA).

114 were identified from a prospectively managed cancer center database and analyzed using univariate and

115 oscopy course (2014 Memorial Sloan Kettering Cancer Center dermoscopy course).

116 to 50% of patients with cancer in community cancer centers did not report discussing, getting advice

117 ions suggest that treatment at a high-volume cancer center employing a standardized clinical pathway

118 titute-designated comprehensive and clinical cancer centers for oncology trials using advanced imagin

119 In order to meet that challenge, four cancer centers formed the Text Information Extraction Sy

120 by grant H021 from DKFZ-HIPO, the University Cancer Center Frankfurt, and the Frankfurt Research Fund

121 Clinical advertisements by cancer centers frequently promote cancer therapy with em

122 ear HCT survivors treated at a comprehensive cancer center from 1992 through 2009 who were Washington

123 eated at The University of Texas MD Anderson Cancer Center from 1993 to 2007 and 4,590 patients from

124 l genetics service at a single tertiary care cancer center from 1998 through 2015.

125 isolated from patients at the M.D. Anderson Cancer Center from 2001 to 2010 and assessed their clini

126 r were performed at Memorial Sloan Kettering Cancer Center from 2008 to 2019.

127 ay inhibitor, vismodegib, at a comprehensive cancer center from 2009 through 2015.

128 methylnaltrexone at Memorial Sloan Kettering Cancer Center from 2009-2016.

129 ord review was conducted at a large tertiary cancer center from a prospectively maintained database f

130 HSCT at The University of Texas MD Anderson Cancer Center from January 1, 1997, to December 31, 2011

131 80 PET/CT scans performed at a comprehensive cancer center from January 2007 to January 2015 identifi

132 enting to an outpatient clinic at a tertiary cancer center from June 2006 to July 2009.

133 PS II NSGCT seen at Memorial Sloan Kettering Cancer Center from March 1989 to April 2016 and who were

134 ucted at The University of Texas MD Anderson Cancer Center from May 10, 2011, to March 31, 2017, a to

135 ons of melphalan at Memorial Sloan Kettering Cancer Center from September 12, 2012, through April 15,

136 data were collected from 7 international eye cancer centers from January 1, 1980 through December 31,

137 data were collected from 6 international eye cancer centers from January 1, 1980, through December 31

138 ective multicenter study that involved 6 eye cancer centers from January 1, 1980, through December 31

139 RC conducted at 11 US academic and community cancer centers from March 2012 through November 2016 (da

140 9 were diagnosed at Memorial Sloan Kettering Cancer Center (from a total of 2,035 patients with cance

141 of Health criteria, Memorial Sloan Kettering Cancer Center GIST nomogram, and American Joint Committe

142 Further, the M.D. Anderson Cancer Center group (MDA) and the Japan Pancreas Society

143 thermore, high-volume centers and designated cancer centers had higher readmission rates.

144 ntimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primar

145 addition, high-volume centers and designated cancer centers have higher readmission rates, which may

146 Many cancer centers have not fully implemented evidence-based

147 CLC from The University of Texas MD Anderson Cancer Center (Houston, TX) and 293 cases from the Mayo

148 ystemic therapy were enrolled at MD Anderson Cancer Center (Houston, TX, USA) between Sept 15, 2014,

149 d control groups were treated at MD Anderson Cancer Center (Houston, TX, USA) from 1997 to 2015.

150 ened at The University of Texas, MD Anderson Cancer Center (Houston, TX, USA) in February, 2019, to e

151 eated at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), who fulfilled the diag

152 unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitat

153 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA).

154 tients with high-risk CLL at the MD Anderson Cancer Center (Houston, TX, USA).

155 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA).

156 done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA).

157 done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA).

158 e-arm, phase 2 trial done at the MD Anderson Cancer Center (Houston, TX, USA).

159 nstitutions (University of Texas MD Anderson Cancer Center, Houston, and Siriraj Hospital, Mahidol Un

160 e feasibility trial performed at MD Anderson Cancer Center, Houston, Texas, included 12 patients with

161 urred at the University of Texas MD Anderson Cancer Center, Houston, TX, from 2002 to 2014.

162 We recruited patients at the MD Anderson Cancer Center, Houston, TX, USA, between June, 2010, and

163 en at a National Cancer Institute-designated cancer center (HR, 0.77; 95% CI, 0.62-0.97), and being s

164 e regions as the subset of 27 NCI-Designated Cancer Centers identified as National Comprehensive Canc

165 At a cancer center in Alberta, Canada, consecutive patients w

166 ncer with insomnia recruited from a tertiary cancer center in Calgary, Alberta, Canada, from Septembe

167 ented to the University of Texas MD Anderson Cancer Center in Houston during the period from January

168 at an outpatient supportive care center in a cancer center in Houston, Texas, including English-speak

169 rgery at The University of Texas MD Anderson Cancer Center in Houston, Texas.

170 party EBV-CTLs from Memorial Sloan Kettering Cancer Center in June 2015.

171 sician-scientist at Memorial Sloan Kettering Cancer Center in New York, where his laboratory studies

172 North Shore Cancer Center, a community-based cancer center in northeastern Massachusetts.

173 The study was conducted at a tertiary care cancer center in NYC from March 22, 2020, until August 2

174 ashington Cancer Consortium, a comprehensive cancer center in Seattle that serves the Pacific Northwe

175 hase 2 trial at the Memorial Sloan Kettering Cancer Center in the USA.

176 ients recruited from the Dana-Farber/Harvard Cancer Center in the USA.

177 x musculoskeletal radiologists at a tertiary cancer center in three image groupings.

178 at a federally funded tertiary care referral cancer center in Trujillo, Peru, from February 1 through

179 l (OS) of lung cancer patients of a tertiary cancer center in Yunnan to investigate screening and reg

180 1, 1980, through December 31, 2015, at 6 eye cancer centers in 4 countries.

181 h 27 surgeons from 20 tertiary gynecological cancer centers in Australia, New Zealand, and Hong Kong

182 adenocarcinomas performed at two high-volume cancer centers in London between 2000 and 2010.

183 ospective cohort study including 14 regional cancer centers in Ontario, Canada.

184 melanomas in 134 patients treated in 9 skin cancer centers in Spain, France, Italy, and Austria.

185 group of patients with BPDCN treated at 3 US cancer centers in the modern era but before tagraxofusp

186 rial was undertaken within eight gynecologic cancer centers in the Netherlands.

187 , and December 31, 2012, at 7 major academic cancer centers in the United States and Canada.

188 Patients from 5 liver cancer centers in the United States who had liver resect

189 2009 to 2013 at 4 academic tertiary referral cancer centers in the United States.

190 -institution academic national comprehensive cancer center included 527 consecutive patients with HER

191 al Cancer Institute-designated comprehensive cancer center included all patients undergoing curative-

192 Support Grant CA016672, and the MD Anderson Cancer Center Leukaemia SPORE CA100632 from the National

193 m of Research Excellence and the Leon Berard Cancer Center, Lyon, France.

194 ted death, the experience of a comprehensive cancer center may be informative.

195 encing on 29 TNBC cases from the MD Anderson Cancer Center (MDACC) selected because they had either p

196 recruited from the Memorial Sloan Kettering Cancer Center; Melanoma Unit of the Hospital Clinic, Uni

197 Tumor specimens were collected from Baptist Cancer Center (Memphis, Tennessee) over the course of 9

198 ding increases by hospitals, dental centers, cancer centers, mental health and addiction clinics, and

199 erson Lung Cancer Priority Fund, MD Anderson Cancer Center Moon Shot Initiative, and Cancer Center Su

200 tients diagnosed at Memorial Sloan Kettering Cancer Center (MSK), with a focus on evaluating active s

201 guidelines and the Memorial Sloan Kettering Cancer Center (MSKCC) online nomogram.

202 WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121).

203 WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121).

204 Leibovich; Kattan; Memorial Sloan Kettering Cancer Center [MSKCC]; Yaycioglu; Karakiewicz; and Cindo

205 ata from The University of Texas MD Anderson Cancer Center (n = 3,496).

206 MD Anderson Cancer Center, National Cancer Institute.

207 Cancer centers (NCI-CCs and CoC centers) were more likel

208 groups: National Cancer Institute-Designated Cancer Centers (NCI-CCs), Commission on Cancer (CoC) cen

209 recruited from the Memorial Sloan-Kettering Cancer Center (New York, USA) were assessed.

210 all accuracy of the Memorial Sloan Kettering Cancer Center nomogram was higher in the ePLND+SNB than

211 ions of the updated Memorial Sloan Kettering Cancer Center nomogram.

212 implementation science program at the Butaro Cancer Center of Excellence in Rwanda are described as a

213 nsion at the University of Texas MD Anderson Cancer Center of patients with advanced metaplastic TNBC

214 reatic adenocarcinoma from the Comprehensive Cancer Center of Wake Forest Baptist Medical Center (Win

215 an HSCT from 1997 to 2011 at the MD Anderson Cancer Center of whom 602 (8%) developed a fracture.

216 RTICIPANTS Retrospective study at 2 academic cancer centers of 86 adult patients referred for clinica

217 Here we report how the seven comprehensive cancer centers of Cancer Core Europe have organized thei

218 Many cancer centers offer acupuncture services.

219 e cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.

220 nts or relatives at Memorial Sloan Kettering Cancer Center or three related community hospice program

221 Eye Cancer Center, Beth Israel Comprehensive Cancer Center, or The New York Eye and Ear Infirmary bet

222 al adenocarcinoma were recruited at a single cancer center over a 2-year period.

223 Cancer center patients had a significantly higher Charls

224 Cancer center patients had a significantly higher in-hos

225 Cancer center patients had a significantly longer hospit

226 r center (8.6% [95% CI, 8.1%-9.2%] among NCI cancer center patients vs 6.0% [95% CI, 5.9%-6.1%] among

227 Of the 557 patients, 135 were cancer center patients.

228 ts vs 6.0% [95% CI, 5.9%-6.1%] among non-NCI cancer center patients; odds ratio [OR], 1.13 [95% CI, 1

229 Cancer centers performed better on 3 of 4 process measur

230 Accredited cancer centers performed better on most process and pati

231 A total of 102 cancer centers placed 409 unique clinical advertisements

232 ior nephrectomy and Memorial Sloan-Kettering Cancer Center prognostic group, to receive the combinati

233 ofi Genzyme, University of Texas MD Anderson Cancer Center Prostate Cancer Moon Shot Program, and Sol

234 Cancer center recognition, offered as accreditation by t

235 f oncologists affiliated with NCI-Designated Cancer Centers relative to oncologists excluded from the

236 ion in institutional practice manifest among cancer centers reveals a lack of consensus about optimal

237 hools of public health, medical schools, and cancer centers, revised competencies and training progra

238 Memorial Sloan Kettering Cancer Center risk category was favorable in 26% of pati

239 n was stratified by Memorial Sloan Kettering Cancer Center risk group and papillary histology.

240 cation factors were Memorial Sloan Kettering Cancer Center risk group and the number of previous trea

241 Geriatricians at Memorial Sloan Kettering Cancer Center risk-stratify surgical patients with solid

242 databases at three institutions: MD Anderson Cancer Center, Smilow Cancer Hospital at Yale, and The J

243 ) was analyzed, independent of HV esophageal cancer center status and patient and disease-specific co

244 rson Cancer Center Moon Shot Initiative, and Cancer Center Support (Core), National Cancer Institute,

245 itutes of Health (NIH) through MD Anderson's Cancer Center Support Grant (CA016672).

246 and R01 DE027738, and MSKCC through NIH/NCI Cancer Center Support Grant (P30 CA008748).

247 18694-03); and the Huntsman Cancer Institute Cancer Center Support Grant (P30CA040214).

248 The MD Anderson Cancer Center Support Grant CA016672, and the MD Anderso

249 utes of Health and National Cancer Institute Cancer Center Support Grant P30 CA008748.

250 Treatment of Cancer, NIH through MD Anderson Cancer Center Support Grant, and the MD Anderson MDS & A

251 ichard Spencer Lewis Memorial Foundation and Cancer Center Support Grant.

252 itutes of Health (National Cancer Institute) Cancer Center Support Grant.

253 ion for Health Research and Development, NCI Cancer Center Support, NCI Clinical and Translational Sc

254 al Cancer Institute-designated Comprehensive Cancer Centers, sustained counseling and provision of fr

255 cohort of 5,363 patients treated at Moffitt Cancer Center (Tampa, FL).

256 l Cancer Care biobanking protocol at Moffitt Cancer Center (Tampa, FL, USA) between Jan 1, 2006, and

257 an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advance

258 a breast MRI database from a large regional cancer center, the authors retrospectively identified al

259 nal Review Board at Memorial Sloan Kettering Cancer Center, the FDA, and the National Marrow Donor Pr

260 Results In regions containing NCI-Designated Cancer Centers, there were 13.7 oncologists per 100,000

261 f oncologists associated with NCI-Designated Cancer Centers; this relationship held when considering

262 ished nomogram from Memorial Sloan-Kettering Cancer Center to predict for risk of IBTR in patients wi

263 ced solid tumors at Memorial Sloan Kettering Cancer Center to report 12 common symptoms via tablet co

264 fertility program was established at a large cancer center to support clinicians in discussing treatm

265 administered in community-based and academic cancer centers to 287 women 40 years or older with stage

266 e need for specialized designation of rectal cancer centers to support ongoing regionalization of car

267 y of California, San Francisco Comprehensive Cancer Center Tobacco Program.

268 study at the University of Texas MD Anderson Cancer Center, TX, USA.

269 riation in chemotherapy and radiation use by cancer center type, geographical location, and hospital

270 amples from 415 tissues collected from three cancer centers (UM, USC, and KCCRI) were used to assess

271 ceived frontline chemotherapy at MD Anderson Cancer Center underwent gene expression profiling of leu

272 of a prospective clinical trial at the Skin Cancer Center, University Hospital Essen.

273 Graham with 'Norris Comprehensive Cancer Center, University of Southern California, Los An

274 ospective trials at Memorial Sloan Kettering Cancer Center using (18)F-FES PET/CT to evaluate metasta

275 al Cancer Institute-designated comprehensive cancer center varied considerably in how they planned to

276 he disease-specific survival adjusted by eye cancer center was better in patients who had received ri

277 y collected data at Memorial-Sloan Kettering Cancer Center was conducted.

278 A random sample of 450 oncologists from 45 cancer centers was selected from the American Medical As

279 tudy conducted in three French comprehensive cancer centers was to evaluate the therapeutic impact on

280 (CAR T) therapy at Memorial Sloan Kettering Cancer Center, we aimed to identify clinical variables a

281 udy from The University of Texas MD Anderson Cancer Center, we assessed the associations of 19,830 co

282 At Memorial Sloan Kettering Cancer Center, we have focused our energies on imaging s

283 th CNS inflammatory diseases at the National Cancer Center were analysed using cell-based assays for

284 2014 at The University of Texas MD Anderson Cancer Center were identified and immunophenotypically c

285 2017 at The University of Texas MD Anderson Cancer Center were identified.

286 2018 at The University of Texas MD Anderson Cancer Center were included in the analysis.

287 b at The Ohio State University Comprehensive Cancer Center were included.

288 ber 2009 and October 2014 at the MD Anderson Cancer Center were included.

289 ans from 2002 to 2013 at the Peter MacCallum Cancer Center were retrospectively analyzed, and a syste

290 atients from 2000 to 2010 at the MD Anderson Cancer Center were used to develop the clinical predicti

291 a (DLBCL) diagnosed from 2000-2010 at 7 NCCN cancer centers were assessed for their prognostic signif

292 Seven eye cancer centers were involved in the study.

293 al Cancer Institute-designated comprehensive cancer centers were randomly sampled and surveyed to eva

294 other concurrent patients at the MD Anderson Cancer Center who were eligible for this trial but decli

295 ort study of adult patients at an ambulatory cancer center with URI diagnoses from 1 October 2015 to

296 rt study, genomic DNA of women from 12 major cancer centers with a first diagnosis of invasive breast

297 enitourinary, or breast cancer at a tertiary cancer center, with access to a home computer and prior

298 single National Cancer Institute-designated cancer center within a quaternary academic medical cente

299 National Cancer Institute (NCI) -designated cancer centers within federal exchange networks.

300 sive Cancer Network-designated comprehensive cancer center) within one metropolitan health system fro